Roivant Sciences Ltd’s filing revealed that its President & COO Venker Eric unloaded Company’s shares for reported $1.02 million on Apr 21 ’25. In the deal valued at $10.22 per share,100,000 shares were sold. As a result of this transaction, Venker Eric now holds 1,116,345 shares worth roughly $12.92 million.
Then, Venker Eric bought 100,000 shares, generating $1,022,374 in total proceeds.
Before that, Venker Eric sold 434,478 shares. Roivant Sciences Ltd shares valued at $4,701,052 were divested by the President & COO at a price of $10.82 per share. As a result of the transaction, Venker Eric now holds 1,127,290 shares, worth roughly $13.04 million.
Wolfe Research initiated its Roivant Sciences Ltd [ROIV] rating to an Outperform in a research note published on February 15, 2024; the price target was $17. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Deutsche Bank began covering ROIV with “Buy” recommendation on December 12, 2023. Guggenheim started covering the stock on October 17, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 0.78% to $11.57. Over the last five days, the stock has gained 3.40%. Roivant Sciences Ltd shares have fallen nearly -2.20% since the year began. Nevertheless, the stocks have risen 3.21% over the past one year. While a 52-week high of $13.06 was reached on 01/02/25, a 52-week low of $8.73 was recorded on 04/07/25. SMA at 50 days reached $10.49, while 200 days put it at $11.26.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 11.40, which if violated will result in even more drops to 11.24. On the upside, there is a resistance level at 11.69. A further resistance level may holdings at 11.82. The Relative Strength Index (RSI) on the 14-day chart is 67.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 10.67%. Stochastics %K at 88.48% indicates the stock is a selling.
The most recent change occurred on June 08, 2023 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $10.50 price target.
